Docetaxel + TroVax
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone Refractory Prostate Cancer
Conditions
Hormone Refractory Prostate Cancer
Trial Timeline
Aug 1, 2010 → Mar 1, 2013
NCT ID
NCT01194960About Docetaxel + TroVax
Docetaxel + TroVax is a phase 2 stage product being developed by Oxford Biomedica for Hormone Refractory Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01194960. Target conditions include Hormone Refractory Prostate Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01194960 | Phase 2 | Terminated |
Competing Products
20 competing products in Hormone Refractory Prostate Cancer